Literature DB >> 23378293

Raltegravir resistance in the cerebrospinal fluid.

B Mora-Peris1, N E Mackie, D Suan, D A Cooper, B J Brew, A Winston.   

Abstract

We report the first published case of integrase inhibitor resistance in the central nervous system compartment in the absence of evidence of integrase inhibitor resistance in the plasma of a patient without human immunodeficiency virus (HIV)-encephalitis in the context of other HIV-associated central nervous system infections.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23378293     DOI： 10.1007/s15010-013-0409-z

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  12 in total

1.  Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.

Authors:  Andrea Antinori; Maria Letizia Giancola; Susanna Grisetti; Fabio Soldani; Lucia Alba; Giuseppina Liuzzi; Alessandra Amendola; Maria Capobianchi; Valerio Tozzi; Carlo Federico Perno
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

2.  Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Authors:  Timothy Rawson; David Muir; Nicola E Mackie; Lucy J Garvey; Alex Everitt; Alan Winston
Journal:  J Infect       Date:  2012-04-17       Impact factor: 6.072

3.  HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.

Authors:  Serena S Spudich; Wei Huang; Annelie C Nilsson; Christos J Petropoulos; Teri J Liegler; Jeannette M Whitcomb; Richard W Price
Journal:  J Infect Dis       Date:  2005-02-09       Impact factor: 5.226

4.  Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid.

Authors:  P H Cunningham; D G Smith; C Satchell; D A Cooper; B Brew
Journal:  AIDS       Date:  2000-09-08       Impact factor: 4.177

5.  HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Authors:  Arvid Edén; Dietmar Fuchs; Lars Hagberg; Staffan Nilsson; Serena Spudich; Bo Svennerholm; Richard W Price; Magnus Gisslén
Journal:  J Infect Dis       Date:  2010-11-04       Impact factor: 5.226

6.  Emergence of raltegravir-resistant HIV-1 in the central nervous system.

Authors:  K Watanabe; M Honda; T Watanabe; K Tsukada; K Teruya; Y Kikuchi; S Oka; H Gatanaga
Journal:  Int J STD AIDS       Date:  2010-12       Impact factor: 1.359

7.  HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis.

Authors:  Cathia Soulié; Slim Fourati; Sidonie Lambert-Niclot; Roland Tubiana; Ana Canestri; Pierre-Marie Girard; Christine Katlama; Laurence Morand-Joubert; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

8.  Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis.

Authors:  Sergio Monteiro de Almeida; Archana Bhatt; Patricia K Riggs; Janis Durelle; Deborah Lazzaretto; Jennifer Marquie-Beck; Allen McCutchan; Scott Letendre; Ronald Ellis
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

9.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

10.  Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.

Authors:  Aylin Yilmaz; Magnus Gisslén; Serena Spudich; Evelyn Lee; Anura Jayewardene; Francesca Aweeka; Richard W Price
Journal:  PLoS One       Date:  2009-09-01       Impact factor: 3.240
View more
  1 in total

1.  Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.

Authors:  Michael J Peluso; Serena Spudich
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.